You are here: Industry Insights > AstraZeneca

News List

AstraZeneca teams with Geisinger on EHR apps to get asthma patients talking to their doctors fiercepharma
August 01, 2018
AstraZeneca and Geisinger want to get asthma patients talking—to their doctors. And they're rolling out a new suite of digital apps to help make that happen.
AstraZeneca divests Atacand’s European rights for $210m pharmaceutical-technology
July 30, 2018
AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to German pharmaceutical company Cheplapharm Arzneimittel for $200m.
AstraZeneca H1 results: new drugs and emerging markets fuel growth pharmaceutical-technology
July 30, 2018
AstraZeneca has announced new medicines and emerging markets have driven its growth in the first half (H1) of 2018. This has been partially offset by the loss of Crestor exclusivity in Europe and Japan.
Deals this week: AstraZeneca, Biogen, Midatech Pharma pharmaceutical-technology
July 30, 2018
AstraZeneca has agreed to sell the European commercial rights of its Atacand and Atacand Plus drugs to Cheplapharm Arzneimittel.
EuroBiotech Report—AstraZeneca cancer trial, GSK attempts R&D turnaround, Sanofi digital investment and more fiercepharma
July 30, 2018
Welcome to the latest edition of our weekly EuroBiotech Report. Our top stories this week center on AstraZeneca seeing its Array-licensed MEK drug fail in another cancer setting....
Q2 results roundup - 27 July pharmatimes
July 30, 2018
Amgen has posted higher sales in Q2 2018 boosted by double-dgitig growth from some of its recently launched products. Revenue rose by 4% to $6.1 billion, above forecasts $5.7 billion. CEO Robert Bradway noted that "our two most recently launched products,
AstraZeneca divests Atacand’s European rights for $210m pharmaceutical-technology
July 27, 2018
AstraZeneca has signed an agreement to sell the European commercial rights for its Atacand (candesartan cilexetil) drug to German pharmaceutical company Cheplapharm Arzneimittel for $200m.
AstraZeneca H1 results: new drugs and emerging markets fuel growth pharmaceutical-technology
July 27, 2018
AstraZeneca has announced new medicines and emerging markets have driven its growth in the first half (H1) of 2018. This has been partially offset by the loss of Crestor exclusivity in Europe and Japan.
AstraZeneca Brexit prep to cost £40M as it duplicates drug testing, boosts stockpiles fiercepharma
July 27, 2018
As the date for Brexit fast approaches, drugmakers are bracing for impact, and AstraZeneca is one of them. The U.K.-based pharma has taken up three lines of defense to forestall potential supply disruptions.
AstraZeneca sells European rights for heart failure treatment for $210M biospectrumasia
July 25, 2018
Cheplapharm would pay AstraZeneca $200m on completion of the agreement, expected to be finalised in the third quarter of 2018, plus a time-bound payment of $10m and sales-contingent milestones.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page